['beta-thalassemia']
['bitopertin']

        Inclusion Criteria:

          -  Confirmed diagnosis of beta-thalassemia

          -  Clinically defined non-transfusion-dependent anemia (Part 1 only), defined as Hb
             concentrations >7.5 grams per deciliter (g/dL) and <9.5 g/dL, less than or equal to 4
             transfusions of red blood cell units within 1 year prior to study enrollment, and no
             transfusion within 12 weeks prior to study enrollment

          -  Completion of 16 weeks of treatment with bitopertin in Part 1 of this study with more
             than 80% compliance from expected use of study medication (based on patient diary and
             study drug accountability; Part 2 only)

          -  A favorable benefit-risk ratio from treatment with bitopertin as assessed by the
             Investigator (Part 2 only)

        Exclusion Criteria:

          -  Any history of gene therapy

          -  History of hemolytic anemia except for beta-thalassemia

          -  Severe symptomatic splenomegaly and/or hepatomegaly with hypersplenism (Part 1 only)

          -  Any use of an erythropoiesis-stimulating agent within 24 weeks prior to enrollment.

          -  Initiation of iron chelation therapy or hydroxyurea within 24 weeks prior to
             enrollment (Part 1 only)

          -  Depression, treatment with anti-depressants, or other psychiatric illnesses and/or
             drug abuse

          -  Clinically significant/uncontrolled comorbid disease

          -  Pregnant or breastfeeding females

          -  Use of cytochrome P450 (CYP) 3A4 inhibitors within 2 weeks or CYP3A4 inducers within 4
             weeks prior to study drug

          -  Active hepatitis B or C or known positive human immunodeficiency virus (HIV) test
             result

          -  Diagnosis of cancer within previous 5 years unless treatment has resulted in complete
             freedom from disease for at least 2 years

          -  Any major illness within 1 month or febrile illness within 1 week prior to study drug

          -  Pulmonary hypertension requiring oxygen therapy (Part 1 only)
      